Cargando…
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer
Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that 3-dimensional (3D) chromatin interactions both within and between topologically associating domains (TADs) frequently ch...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965612/ https://www.ncbi.nlm.nih.gov/pubmed/31949157 http://dx.doi.org/10.1038/s41467-019-14098-x |
_version_ | 1783488650990845952 |
---|---|
author | Achinger-Kawecka, Joanna Valdes-Mora, Fatima Luu, Phuc-Loi Giles, Katherine A. Caldon, C. Elizabeth Qu, Wenjia Nair, Shalima Soto, Sebastian Locke, Warwick J. Yeo-Teh, Nicole S. Gould, Cathryn M. Du, Qian Smith, Grady C. Ramos, Irene R. Fernandez, Kristine F. Hoon, Dave S. Gee, Julia M. W. Stirzaker, Clare Clark, Susan J. |
author_facet | Achinger-Kawecka, Joanna Valdes-Mora, Fatima Luu, Phuc-Loi Giles, Katherine A. Caldon, C. Elizabeth Qu, Wenjia Nair, Shalima Soto, Sebastian Locke, Warwick J. Yeo-Teh, Nicole S. Gould, Cathryn M. Du, Qian Smith, Grady C. Ramos, Irene R. Fernandez, Kristine F. Hoon, Dave S. Gee, Julia M. W. Stirzaker, Clare Clark, Susan J. |
author_sort | Achinger-Kawecka, Joanna |
collection | PubMed |
description | Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that 3-dimensional (3D) chromatin interactions both within and between topologically associating domains (TADs) frequently change in ER+ endocrine-resistant breast cancer cells and that the differential interactions are enriched for resistance-associated genetic variants at CTCF-bound anchors. Ectopic chromatin interactions are preferentially enriched at active enhancers and promoters and ER binding sites, and are associated with altered expression of ER-regulated genes, consistent with dynamic remodelling of ER pathways accompanying the development of endocrine resistance. We observe that loss of 3D chromatin interactions often occurs coincidently with hypermethylation and loss of ER binding. Alterations in active A and inactive B chromosomal compartments are also associated with decreased ER binding and atypical interactions and gene expression. Together, our results suggest that 3D epigenome remodelling is a key mechanism underlying endocrine resistance in ER+ breast cancer. |
format | Online Article Text |
id | pubmed-6965612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-69656122020-01-22 Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer Achinger-Kawecka, Joanna Valdes-Mora, Fatima Luu, Phuc-Loi Giles, Katherine A. Caldon, C. Elizabeth Qu, Wenjia Nair, Shalima Soto, Sebastian Locke, Warwick J. Yeo-Teh, Nicole S. Gould, Cathryn M. Du, Qian Smith, Grady C. Ramos, Irene R. Fernandez, Kristine F. Hoon, Dave S. Gee, Julia M. W. Stirzaker, Clare Clark, Susan J. Nat Commun Article Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that 3-dimensional (3D) chromatin interactions both within and between topologically associating domains (TADs) frequently change in ER+ endocrine-resistant breast cancer cells and that the differential interactions are enriched for resistance-associated genetic variants at CTCF-bound anchors. Ectopic chromatin interactions are preferentially enriched at active enhancers and promoters and ER binding sites, and are associated with altered expression of ER-regulated genes, consistent with dynamic remodelling of ER pathways accompanying the development of endocrine resistance. We observe that loss of 3D chromatin interactions often occurs coincidently with hypermethylation and loss of ER binding. Alterations in active A and inactive B chromosomal compartments are also associated with decreased ER binding and atypical interactions and gene expression. Together, our results suggest that 3D epigenome remodelling is a key mechanism underlying endocrine resistance in ER+ breast cancer. Nature Publishing Group UK 2020-01-16 /pmc/articles/PMC6965612/ /pubmed/31949157 http://dx.doi.org/10.1038/s41467-019-14098-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Achinger-Kawecka, Joanna Valdes-Mora, Fatima Luu, Phuc-Loi Giles, Katherine A. Caldon, C. Elizabeth Qu, Wenjia Nair, Shalima Soto, Sebastian Locke, Warwick J. Yeo-Teh, Nicole S. Gould, Cathryn M. Du, Qian Smith, Grady C. Ramos, Irene R. Fernandez, Kristine F. Hoon, Dave S. Gee, Julia M. W. Stirzaker, Clare Clark, Susan J. Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer |
title | Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer |
title_full | Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer |
title_fullStr | Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer |
title_full_unstemmed | Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer |
title_short | Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer |
title_sort | epigenetic reprogramming at estrogen-receptor binding sites alters 3d chromatin landscape in endocrine-resistant breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965612/ https://www.ncbi.nlm.nih.gov/pubmed/31949157 http://dx.doi.org/10.1038/s41467-019-14098-x |
work_keys_str_mv | AT achingerkaweckajoanna epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT valdesmorafatima epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT luuphucloi epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT gileskatherinea epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT caldoncelizabeth epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT quwenjia epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT nairshalima epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT sotosebastian epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT lockewarwickj epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT yeotehnicoles epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT gouldcathrynm epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT duqian epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT smithgradyc epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT ramosirener epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT fernandezkristinef epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT hoondaves epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT geejuliamw epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT stirzakerclare epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer AT clarksusanj epigeneticreprogrammingatestrogenreceptorbindingsitesalters3dchromatinlandscapeinendocrineresistantbreastcancer |